Panobinostat Reverses HepaCAM Gene Expression and Suppresses Proliferation by Increasing Histone Acetylation in Urologic neoplasms

Mechanisms of antitumor effect of Panobinostat with overexpressed hepaCAM in Urologic neoplasms

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040627

Enrollment

Unknown

Registered

2020-12-04

Start date

2020-12-31

Completion date

Unknown

Last updated

2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urologic neoplasms

Interventions

3 groups:No Interventions

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Urologic neoplasms included prostate cancer and bladder cancer.

Exclusion criteria

Exclusion criteria: Non-urological tumors

Design outcomes

Primary

Measure	Time frame
Ac-H3K9;	—

Countries

China

Contacts

Public ContactChun-Li Luo

Chongqing Medical University

luochunli78@126.com+86 15826186636

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026